Last reviewed · How we verify
Erbitux
At a glance
| Generic name | Erbitux |
|---|---|
| Also known as | Cetuximab, cetuximab |
| Sponsor | Hellenic Oncology Research Group |
| Target | Epidermal growth factor receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Head and neck cancer
- Malignant tumor of colon
- Rectal cancer with wild-type RAS
- Squamous cell carcinoma of larynx
- Squamous cell carcinoma of mouth
- Squamous cell carcinoma of nose
- Squamous cell carcinoma of pharynx
Common side effects
- Cutaneous adverse reactions (rash, pruritus, nail changes)
- Headache
- Diarrhea
- Infection
- Fatigue
- Nausea
- Dermatitis acneiform
- Abdominal pain
- Decreased appetite
- Arthralgia
- Rash
- Salivary gland toxicity
Serious adverse events
- Infusion reaction (allergic reaction/anaphylactoid reaction)
- Grade 3 or 4 late radiation toxicities
Key clinical trials
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (PHASE2)
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (PHASE1)
- Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment (PHASE3)
- Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer (PHASE1)
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (PHASE2)
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erbitux CI brief — competitive landscape report
- Erbitux updates RSS · CI watch RSS
- Hellenic Oncology Research Group portfolio CI